G
Glenn J. Lesser
Researcher at Wake Forest University
Publications - 212
Citations - 5236
Glenn J. Lesser is an academic researcher from Wake Forest University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 35, co-authored 170 publications receiving 4237 citations. Previous affiliations of Glenn J. Lesser include University of Rochester & Wake Forest Baptist Medical Center.
Papers
More filters
Journal ArticleDOI
Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Stuart A. Grossman,Xiaobu Ye,Glenn J. Lesser,Andrew E. Sloan,Hetty E. Carraway,Serena Desideri,Steven Piantadosi +6 more
TL;DR: Severe reductions in CD4 counts in patients with newly diagnosed HGG treated with radiation and temozolomide treatment are common, treatment-related, long-lasting, and associated with early death from tumor progression.
Journal ArticleDOI
A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.
Jerome M. Butler,L. Douglas Case,James N. Atkins,Bart Frizzell,George Sanders,Patricia C. Griffin,Glenn J. Lesser,Kevin P. McMullen,Richard P. McQuellon,Michelle J. Naughton,Stephen R. Rapp,Volker W. Stieber,Edward G. Shaw +12 more
TL;DR: Prophylactic use of d-MPH in brain tumor patients undergoing RT did not result in an improvement in QOL and there was no difference in fatigue between patient groups.
Journal ArticleDOI
Treatment of Relapsed Central Nervous System Lymphoma with High-Dose Methotrexate
Scott R. Plotkin,Rebecca A. Betensky,Fred H. Hochberg,Stuart A. Grossman,Glenn J. Lesser,L. Burt Nabors,Brian H. Chon,Tracy T. Batchelor +7 more
TL;DR: It is indicated that high-dose methotrexate remains effective for relapsed central nervous system lymphoma in patients who initially respond to metotrexate and raise the possibility of deferring more toxic salvage regimens in this select group of patients.
Journal ArticleDOI
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
Adrienne Johnson,Eric Allan Severson,Jo-Anne Vergilio,Julia A. Elvin,James Suh,Sugganth Daniel,Mandy Covert,Garrett M. Frampton,Sigmund Hsu,Glenn J. Lesser,Kimberly Stogner-Underwood,Ryan T. Mott,Sarah Rush,Jennifer Stanke,Sonika Dahiya,James Sun,Prasanth Reddy,Zachary R. Chalmers,Rachel L. Erlich,Yakov Chudnovsky,David Fabrizio,Alexa B. Schrock,Siraj M. Ali,Vincent A. Miller,Philip J. Stephens,Jeffrey S. Ross,John R. Crawford,Shakti H. Ramkissoon +27 more
TL;DR: The most common alterations across diagnosis and anatomic location are explored and tumor mutational burden and associated genetic factors that may predispose patients to developing a hypermutator phenotype are discussed.
Journal ArticleDOI
Rituximab monotherapy for patients with recurrent primary CNS lymphoma
Tracy T. Batchelor,Stuart A. Grossman,Tom Mikkelsen,Xiaobu Ye,Serena Desideri,Glenn J. Lesser +5 more
TL;DR: Rituximab has been incorporated into some treatment regimens for newly diagnosed and relapsed PCNSL, although it is not known whether this agent will improve outcomes to the extent that it has for patients with systemic DLBCL.